187 related articles for article (PubMed ID: 35586565)
1. Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of PLOD2.
Xu Q; Kong N; Zhao Y; Wu Q; Wang X; Xun X; Gao P
Front Genet; 2022; 13():864655. PubMed ID: 35586565
[TBL] [Abstract][Full Text] [Related]
2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
Zhao C; Liu Y; Ju S; Wang X
Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
5. PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
Li G; Wang X; Liu G
Biomed Res Int; 2021; 2021():5512340. PubMed ID: 34258263
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
7. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
8. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E.
Zhou Z; Yin H; Suye S; He J; Fu C
Front Genet; 2022; 13():1024989. PubMed ID: 36685883
[TBL] [Abstract][Full Text] [Related]
10. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
11. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
13. Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Zhang Z; Zhang X; Huang A
Front Oncol; 2021; 11():718589. PubMed ID: 34485153
[TBL] [Abstract][Full Text] [Related]
14. [STIP1 correlates with tumor immune infiltration and prognosis as a potential immunotherapy target: a pan-cancer bioinformatics analysis].
Guan S; Shen Z; Lin M; Deng H; Fang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jul; 43(7):1179-1193. PubMed ID: 37488801
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
16. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract][Full Text] [Related]
17. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
Zhao Q; Zhang Z; Wu Y
Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma.
Sun Y; Wang S; Zhang X; Wu Z; Li Z; Ding Z; Huang X; Chen S; Jing Y; Zhang X; Ding L; Song Y; Sun G; Ni Y
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944486
[TBL] [Abstract][Full Text] [Related]
19. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
20. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
